Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Lead clinical blood cancer candidate; bispecific ADAPTIR targeting CD123 x CD3. FDA orphan drug designation for AML (Nov 2019). Phase 1a monotherapy dose escalation and Phase 1b dose expansion completed; Phase 1b/2 RAINIER trial in frontline AML (combination with venetoclax + azacitidine) ongoing with dose optimization for RP2D selection.
ALG.APV-527
Phase 1 · ActiveModality: bispecific antibody
Target 4-1BB (CD137) x 5T4
Partnerships Alligator Bioscience AB: collaboration and option agreement (July 20, 2017); 50/50 cost sharing; jointly owned collaboration IP with opt-out points
Indications
Solid tumors(Phase 1)
Status note Lead solid tumor candidate; bispecific ADAPTIR targeting 4-1BB (CD137) x 5T4. Phase 1 dose escalation trial completed; Aptevo and Alligator evaluating next steps for the dose expansion trial.
APVO603
Preclinical · ActiveModality: bispecific antibody
Target 4-1BB (CD137) x OX40 (CD134)
Indications
Solid tumors(Preclinical)
Status note Preclinical bispecific ADAPTIR candidate targeting 4-1BB (CD137) x OX40 (CD134) (targets per 10-K fallback).
APVO711
Preclinical · ActiveModality: bispecific antibody
Target PD-L1 x CD40
Indications
Cancer(Preclinical)
Status note Preclinical bispecific ADAPTIR candidate targeting PD-L1 x CD40 (targets per 10-K fallback).
Partnerships Niowave: 50/50 collaboration agreement (May 25, 2026) to develop up to three radiopharmaceutical oncology programs combining Aptevo proprietary molecules with Niowave radioisotopes; supply agreement plus Niowave equity investment
Indications
Cancer(Discovery)
Status note Up to three radiopharmaceutical oncology programs; candidate names not disclosed in filing.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.